CO5150204A1 - METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT - Google Patents

METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT

Info

Publication number
CO5150204A1
CO5150204A1 CO00015566A CO00015566A CO5150204A1 CO 5150204 A1 CO5150204 A1 CO 5150204A1 CO 00015566 A CO00015566 A CO 00015566A CO 00015566 A CO00015566 A CO 00015566A CO 5150204 A1 CO5150204 A1 CO 5150204A1
Authority
CO
Colombia
Prior art keywords
agonist
selective
naturally occur
administration
treatment
Prior art date
Application number
CO00015566A
Other languages
Spanish (es)
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5150204A1 publication Critical patent/CO5150204A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con nuevos métodos para aumentar el volumen óseo que comprenden la administración de un agonista FP selectivo que no ocurre naturalmente y un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere de tal tratamiento. Esta invención se refiere adicionalmente a un método para tratar o evitar trastornos óseos que comprenden la administración de un agonista FP selectivo que no ocurre naturalmente y un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere de tal tratamiento.The present invention relates to new methods for increasing bone volume that comprise the administration of a non-naturally occurring selective FP agonist and a selective EP1 agonist that does not occur naturally to a subject requiring such treatment. This invention further relates to a method of treating or avoiding bone disorders comprising the administration of a naturally occurring non-naturally occurring FP agonist and a selective EP1 agonist that does not occur naturally to a subject requiring such treatment.

CO00015566A 1999-03-05 2000-03-03 METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT CO5150204A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12292199P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
CO5150204A1 true CO5150204A1 (en) 2002-04-29

Family

ID=22405645

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00015566A CO5150204A1 (en) 1999-03-05 2000-03-03 METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT

Country Status (3)

Country Link
AU (1) AU3385900A (en)
CO (1) CO5150204A1 (en)
WO (1) WO2000051616A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366755A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring ep, selective agonists
EP2305304A4 (en) 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine Immunopotentiating agent comprising ep1 agonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
WO1996036599A1 (en) * 1995-05-18 1996-11-21 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
ID24827A (en) * 1997-09-09 2000-08-24 Procter & Gamble BONE VOLUME IMPROVEMENT METHOD USING NON-NATURAL SELECTIVE FP AGONISTS

Also Published As

Publication number Publication date
AU3385900A (en) 2000-09-21
WO2000051616A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
BR9811780A (en) Bone volume increase method using non-naturally occurring selective fp agonists
IL280818A (en) Methods for producing alpha-galactosidase a compositions
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
MXPA04008068A (en) Method for administering glp-1 molecules.
DE69626660D1 (en) 2-alkylpyrrolidine
AU3084302A (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
PT867178E (en) USE OF AGONISTS NOT ALOSTERICOS DE GABA FOR THE TREATMENT OF SLEEP DISORDERS
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
AP9801269A0 (en) Prostaglandin agonists.
GT199800177A (en) EFFECTIVE COMBINATION FOR THE TREATMENT OF IMPOTENCE.
BR9911917A (en) Compositions comprising gaba and caffeine analogs
IL159714A0 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
EP1173470A4 (en) Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
MXPA04002565A (en) Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation.
MXPA94009086A (en) Therapeutic substituted guanidines.
EP1441718A4 (en) Carbinols for the treatment of neuropathic dysfunction
YU89103A (en) Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
AP1896A (en) The method of treating cancer
JO3446B1 (en) Method for treating primary insomnia
HK1112738A1 (en) Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders
CO5150204A1 (en) METHOD OF INCREASING THE OSEO VOLUME UNDERSTANDING THE ADMINISTRATION OF A SELECTIVE FP AGONIST THAT DOESN'T NATURALLY OCCUR AND A SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT
PL370361A1 (en) Alkyl urea retinoid agonists i
GB2331301C (en) Galanin